Stockscreener 앱 받기
6.65
57.96%
2.44
시간 외 거래:
6.50
-0.15
-2.26%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm - PR Newswire
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline - TMX Newsfile
Capricor Therapeutics (CAPR) Faces Class Action Scrutiny, Is The 88% Undervalued Case Credible? - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
Capricor Therapeutics (CAPR) Soars on Cantor Fitzgerald Upgrade Despite FDA Panel Setback - GuruFocus
Avoiding Lag: Real-Time Signals in (CAPR) Movement - Stock Traders Daily
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval - Sahm
Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And LawsuitsWhat's Changed - Yahoo Finance
Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy? - simplywall.st
Cantor Fitzgerald upgrades Capricor Therapeutics amid FDA review and strong cash position. - Pluang
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCAPR - ACCESS Newswire
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role - Barchart.com
CAPRICOR THERAPEUTICS, INC. 2026: Revenue $14.08M, EPS ($0.7) — 10-Q Summary - TradingView
Tang Capital group discloses 7.1% Capricor (CAPR) ownership in amended 13G - Stock Titan
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP - The AI Journal
CAPR Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Capricor Therapeutics (CAPR) Sees Surge Amid Deramiocel Update - GuruFocus
Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes - kwsn.com
Capricor Surges 67% as FDA Signals Openness to Revised Deramiocel Filing - finance.biggo.com
Capricor Therapeutics jumps 75% amid FDA talks on Duchenne Muscular Dystrophy drug update - pluang.com
Capricor: Stock Now Surging On Fresh BLA UpdatesWhat Investors Must Know (NASDAQ:CAPR) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why is Capricor Therapeutics stock surging today? - Investing.com
Capricor Shares Rise with FDA Review of Latest Duchenne Data, Eyes on August 22 Event - TechStock²
Capricor's DMD therapy deramiocel gets regulatory lifeline, shares surge - FirstWord Pharma
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data - Endpoints News
Capricor Therapeutics jumps as investors focus on ongoing FDA review and fresh deramiocel update - Quiver Quantitative
$Capricor Therapeutics (CAPR.US)$ - moomoo.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Capricor soars on plan to amend DMD filing after adcomm setback - Fierce Biotech
Why Is Capricor Therapeutics Stock Soaring Today?Capricor Therapeutics (NASDAQ:CAPR) - Benzinga
CAPR Stock In Focus As Lancet Data And Analyst Upgrades Collide - timothysykes.com
Capricor stock upgraded at Cantor on plans for lead drug (CAPR) - Seeking Alpha
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans - GuruFocus
CAPR Stock Draws Traders As Lancet Data And Big Upgrade Hit - StocksToTrade
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Capricor Therapeutics (CAPR) Rockets 115% Pre-Market Amid Valuation and Insider Activity Spotlight - GuruFocus
CAPRICOR THERAPEUTICS ($CAPR) Releases Q2 2026 Earnings - Moomoo
CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds - StocksToTrade
Why is Capricor Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Capricor surges on amended plans for lead drug (CAPR:NASDAQ) - Seeking Alpha
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - BNN Bloomberg
CAPR Upgraded by Cantor Fitzgerald -- Price Target Raised to $28.00 - GuruFocus
CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path - Yahoo Finance
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Why Is CAPR Stock Soaring Premarket? This Analyst Sees A New FDA Path For Deramiocel - Stocktwits
$Capricor Therapeutics (CAPR.US)$ Just here to join the fun, let's go up! - moomoo.com
Capricor Therapeutics (CAPR) Q2 2026 Earnings Call: Deramocel BLA Path and FDA Update - TradingKey
Cantor Fitzgerald upgrades Capricor stock rating on regulatory progress By Investing.com - Investing.com Canada
Cantor Fitzgerald upgrades Capricor stock rating on regulatory progress - Investing.com
Key facts: Capricor (NASDAQ:CAPR) Q2 loss $40.7M; HOPE-3 breach suit - TradingView
Capricor Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why - Benzinga
Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and Strategic Pivot - GuruFocus
Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and ... - Yahoo Finance
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Inves - The National Law Review
Kaplan Fox Announces a Securities Class Action Filed Against Capr - The National Law Review
Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASD - The National Law Review
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
Capricor Therapeutics Faces Securities Lawsuit - stl.news
0.52%
0.07%
자본화:
|
볼륨(24시간):